Merck KGaA and Samsung BioLogics extend strategic alliance

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

Merck KGaA and Samsung BioLogics extend strategic alliance

INICIO/Noticias Farmacéuticas | Posted 01/12/2017 0 Post your comment

German drugmaker Merck KGaA (Merck Group) announced on 1 November 2017 that it had signed a ‘Memorandum of Understanding (MoU) with Samsung BioLogics for a strategic alliance on biopharmaceutical manufacturing and biologic[al]s process development’.

The alliance will accelerate process development and clinical material production at small biotech start-ups focusing on novel drug development for which Samsung BioLogics, which is the specialized biotechnology arm of Samsung, acts as a contract manufacturer. Under the agreement, Merck KGaA will provide process development and support technical training, in addition to its Mobius single-use systems to Samsung BioLogics.

Merck KGaA’s Mobius single-use manufacturing systems deliver solutions from buffer and media preparation, bioreactor, clarification, chromatography, virus clearance, ultrafiltration/diafiltration to formulation and fill.

The new MoU is an extension of an MoU signed in 2014 that encompasses a long-term supply agreement where Merck KGaA would provide raw materials for biopharmaceutical manufacturing.

Korean electronics giant Samsung is aggressively pursuing biosimilars [1]. Merck KGaA, on the other hand, sold its biosimilars business to Fresenius Kabi in September 2017 [2].

Reference
1. GaBI Online - Generics and Biosimilars Initiative. Samsung makes biosimilars deal with Biogen Idec [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2017 Dec 1]. Available from: www.gabionline.net/Biosimilars/News/Samsung-makes-biosimilars-deal-with-Biogen-Idec
2. GaBI Online - Generics and Biosimilars Initiative. Fresenius Kabi acquires Merck KGaA’s biosimilars business [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2017 Dec 1]. Available from: www.gabionline.net/Pharma-News/Fresenius-Kabi-acquires-Merck-KGaA-s-biosimilars-business

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: Merck KGaA